Table 1.
Characteristics of the study sample.
| VARIABLE | STRATA | NUMBER (%) | NUMBER (%) | NUMBER (%) |
|---|---|---|---|---|
| Group | Overall sample (Median age 55; range 18-96) |
Among ≤65 years (Median age 49; range 18-65) |
Among >65 years (Median age 71; range 66-96) |
|
| Total | 1,182 (100) | 875 (100) | 307 (100) | |
| Sex | Female | 631 (53.38) | 495 (56.57) | 136 (44.30) |
| Male | 551 (46.62) | 380 (43.43) | 171 (55.70) | |
| Third dose | Yes | 1055 (89.26) | 771 (88.11) | 284 (92.51) |
| No | 127 (10.74) | 104 (11.89) | 23 (7.49) | |
| Anti-N IgG status at T12 | Positive | 406 (34.35) | 320 (36.57) | 86 (28.01) |
| Negative | 650 (55.0) | 441 (50.4) | 209 (68.08) | |
| Missing | 126 (10.66) | 114 (13.03) | 12 (3.91) | |
| Suppressor drugs | Yes | 36 (0.30) | 1 (0.11) | 35 (11.40) |
| No | 1146 (0.97) | 874 (99.89) | 272 (88.60) | |
| mRNA vaccines during primary cycle | Yes | 946 (80.03) | 687 (78.51) | 259 (84.36) |
| No | 236 (19.97) | 188 (21.49) | 48 (15.64) |